Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807065 · ClinicalTrials.gov registry record · Phase 2
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT01807065 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 51 participants.
The verdict
NCT01807065, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer. Vaccines may help the body build an effective immune response to kill tumor cells. Radiation therapy uses high energy x rays to kill tumor cells. It is not yet known whether giving sipuleucel-T vaccine is more effective with or without radiation therapy in treating prostate cancer
Interventions
- OTHER laboratory biomarker analysis
- RADIATION external beam radiation therapy
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-06-07 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807065
The ClinicalTrials.gov registry entry for NCT01807065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01807065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807065 about?
NCT01807065 is a clinical study titled "Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer". This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer. Vaccines may help the body build an effective immune response to kill tumor cells. Radiation therapy uses high energy x ...
What is the current status of trial NCT01807065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2013-06-07. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT01807065?
The interventions under investigation include: laboratory biomarker analysis (OTHER), external beam radiation therapy (RADIATION), sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01807065?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.